LangdonLMillerMD

Oncology • Seattle, WA

Principal/Consultant

Join to view full profile

Dr. Miller is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Miller's full profile

Already have an account?

Office
Sound Clinical Solutions
3057 Perkins Ln W
Seattle, WA 98199
Phone+1 908-906-6471

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1985 - 1989
University of California, San FranciscoFellowship, Tumor Immunology, 1983 - 1985
University of MinnesotaChief Residency, Internal Medicine, 1982 - 1983
University of MinnesotaResidency, Internal Medicine, 1979 - 1982
Northwestern University The Feinberg School of MedicineClass of 1979

Certifications & Licensure

MI State Medical License 1996 - 2025
MD State Medical License 1989 - 1995
CA State Medical License 1983 - 1989
MN State Medical License 1980 - 1988
American Board of Internal Medicine Internal Medicine

Clinical Trials

A Study of LAM-003 in Patients With Acute Myeloid Leukemia Start of enrollment: 2018 Jan 16
Completed
Phase 1
A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) Start of enrollment: 2020 Oct 07
TERMINATED
PHASE2

Publications & Presentations

PubMed

59 citations
ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models
Tiziana Vaisitti, Francesca Arruga, Nicoletta Vitale, Thanh-Trang Lee, Mira Ko
Blood. 2021-06-17
194 citations
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia
Susan O'Brien, Nicole Lamanna, Thomas J. Kipps, Ian W. Flinn, Andrew D. Zelenetz
Blood. 2015-12-17
492 citations
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
Jennifer R. Brown, John C. Byrd, Steven Coutre, Don M. Benson, Ian W. Flinn
Blood. 2014-05-29

Abstracts/Posters

LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Disease
Langdon L Miller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019